CalciMedica Inc. (NASDAQ:CALC) Stock Has Average Price Target of $50.00 According to AnalystsDefense World · Oct 12, 2026
CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 8, 2026
CalciMedica Announces One-for-Five Reverse Stock SplitGlobeNewsWire · Aug 27, 2026
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational EndpointsPRNewsWire · Jul 29, 2026CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$1.43 | -$2.25 | Miss |
| May 13, 2026 | -$1.40 | -$1.50 | Miss |
| Mar 26, 2026 | -$2.75 | -$3.40 | Miss |
| Nov 12, 2025 | -$2.06 | -$2.60 | Miss |
| Aug 11, 2025 | -$2.00 | -$2.00 | Beat |
| May 14, 2025 | -$2.15 | -$1.80 | Beat |